Editas Medicine Stock Forecast & Predictions: 1Y Price ... Editas Medicine is followed by the analysts listed above. Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and EDIT is experiencing slight selling pressure. The average price target represents a -8.74% change from the last price of $65.53. Yesterday, biotech company Editas Medicine (NASDAQ:EDIT) shared positive preclinical results for one of its cancer treatments. EDIT | Editas Medicine Inc. Analyst Estimates | MarketWatch EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. Editas Stock Price | EDIT - 35.35 -0.92 (-2.5364999999999998%) Side-by-Side View. The stock's last reported lowest price was 35.06. View real-time stock prices and stock quotes for a full financial overview. Overall, given the vast institutional interest, its stable financial position, and the success of similar gene therapeutics in the industry, Editas is a risky but high-reward stock to buy. Editas Medicine Inc - EDIT - Stock forecast - 3 months ... holmes.michael.p Nov 9. Created with Highcharts 9.1.2. EDIT Stock Continues Its Dive. On average, analysts forecast that BABA's EPS will be $8.30 for 2022, with the lowest . In a nutshell, if Editas Medicine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. EDIT Stock Forecast, Price & News (Editas Medicine) 1/8 . 28.71 52 Week . Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? Now that you know more about Editas Medicine Inc stands, let's learn more about the future of the company. Nasdaq Global Select. Over the past year, it has more than doubled investors . Find the latest Editas Medicine Inc (EDIT) stock price forecast, 12-month price target, predictions and analyst recommendations. Editas Medicine, Inc. (EDIT) Stock Price, Quote & News ... Editas Medicine Inc. (EDIT) estimates and forecasts Frankfurt Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's 8EM shares and potentially its market environment have been in a bullish cycle in the last 12 months . Editas Medicine ( EDIT) - Get Editas Medicine, Inc. Report dropped Friday after analysts at Goldman Sachs initiated coverage on shares off the company with a sell rating and a price target of $20 . Editas Medicine Falls as Goldman Initiates the Stock at ... Editas Medicine (EDIT) Stock Return: AI Predicts EDIT Average and Excess Return After a Fall or Rise. 33% vs Avg. Editas Medicine (EDIT) Stock Price, News & Info | The ... Some of the losses seen by insiders who purchased US$1.4m worth of Editas Medicine, Inc. (NASDAQ:EDIT) shares over the past year were recovered after the stock increased by 6.8% over the past week.The purchase, however, has proven to be a pricey bet, with losses currently totalling US$250k. Toggle Chart Options. The resulting number helps traders determine whether the premium of an option is "fair" or not. Editas Medicine Inc. analyst ratings, historical stock prices, earnings estimates & actuals. To hit the forecast high, the stock's price needs a -23.31% plunge from its current level, while the stock would need to tank 64.99% for it to hit the projected low. Advanced Charting. $18.03. View EDIT's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. At Editas Medicine, we are using this technology to develop transformative and durable medicines for people living with serious diseases. Analyst Ratings For Editas Medicine. Editas Medicine is selling for under 35.35 as of the 22nd of November 2021; that is -2.54 percent decrease since the beginning of the trading day. Over the next 52 weeks, Editas Medicine Inc has on average historically risen by 20.1 % based on the past 5 years of stock performance. Volume is the number of shares traded in a given period. This article is for informational purposes only. CRISPR (pronounced "crisper") is an acronym for "Clustered, Regularly Interspaced, Short Palindromic Repeats," and refers to a recently developed gene editing technology that can revise, remove, and . A company's earnings reviews provide a brief indication of a stock's direction in the short term, where in the case of Editas Medicine Inc. 1 upward and no downward comments were posted in the last 7 days. What this means: InvestorsObserver gives Editas Medicine (EDIT) an overall rank of 33, which is below average. EDIT closed down 7.69 percent on Friday, December 3, 2021, on 1.57 times normal volume. Find the latest Editas Medicine, Inc. EDIT analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. It operates through the developing and commercializing genome editing technology segment. Post-Market 0.38 (1.33%) The bar color helps to visualize whether volume is weighted towards buys or sells. investment rating. Editas Stock Forecast. View Editas Medicine, Inc. EDIT investment & stock information. As an investor, you can get an idea of where the stock is trending by the forecast and beta. As is evident from the statistics, the company's shares have fallen -12.05 percent over the past six months and at a -79.80% annual growth rate that is well below the . EDIT updated stock price target summary. [9/30/2021] Editas Medicine (EDIT) Stock Price Forecast: AI Forecasts EDIT Stock Price To Be Around $53.60 In A Month (Up 26%) 2021-09-30. It is calculated by dividing a company's price per share by its earnings per share. Price Target. The Editas Medicine, Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business. This suggests a possible upside of 99.7% from the stock's current price. Jan. 26, 2021, 06:30 AM. EDIT : Editas Medicine stock forecast by Wall Street Analysts. ( 69.11% upside) Analyst Consensus: Buy. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Case 2: Editas stock rises by 5% or more in a week. View Editas Medicine, Inc. EDIT investment & stock information. Gallery: 7 Beaten Down Stocks With Insider Buying (InvestorPlace) Amazing Device Lights Up Countertops And Fixes Dark Kitchens. It's tough to imagine a world where biotechnology advances but leaves CRISPR Therapeutics behind. APVO Aptevo Therapeutics. Written By Chung Hieu Bui. High volatility in Editas Medicine, Inc stock price on Thursday which ended trading at $27.83The Editas Medicine, Inc stock price fell by -7.05% on the last . The company's revenue is forecast to drop by -79.00% over what it did in 2021. Over the past year the S&P 500 is up 17.69% while EDIT has risen 67.25%. Stock Quote & Chart. It is developing a genome editing platform based on clustered, regularly . EDIT stock fares better after Case 2, with an expected return of 1.7% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an expected return of 3.6% for Case 2 . Full screen. According to analyst projections, EDIT's forecast low is $23.00 with $81.00 as the target high. holmes.michael.p Nov 9. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Case 1: Editas stock drops by -5% or more in a week. APVO Stock Forecast, Price Targets and Analysts Predictions - TipRanks. Date Range. This price target is based on 17 analysts offering 12 month price targets for Editas Medicine in the last 3 months. High volatility in Editas Medicine, Inc stock price on Thursday which ended trading at $27.83The Editas Medicine, Inc stock price fell by -7.05% on the last . Given the current short-term trend, the stock is expected to fall -43.23% during the next 3 months and, with a 90% probability hold a price between $9.06 and $21.32 at the end of this 3-month period. Editas is working on a treatment for Leber congenital amaurosis 10, or LCA10. This is a small company with massive potential. Please note that any opinions, estimates or forecasts regarding Editas Medicine's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Editas Medicine or its management. Intraday data delayed at least 15 minutes or per . The inherited condition is the most common cause of genetic childhood blindness, Editas . The Company is focused on developing transformative gene-editing medicines to treat a range of serious diseases. $52.07. Price as of December 13, 2021, 4:00 p.m. The number of outstanding shares for Editas Medicine Inc is 68261000. The average price target represents a 71.97% upside from the last price of $33.30. Case 1: Editas stock drops by -5% or more in a week. Oct 1. 1D 5D 1M 3M 6M YTD 1Y 3Y All Range Dropdown. Turning out attention to how the Editas Medicine Inc. stock has performed in comparison to its peers in the industry, here's what we find: EDIT's stock is -7.69% on the day and -16.58% in the past 12 months, while Molecular Templates Inc. (MTEM) traded -7.53% in the last session and was positioned -54.08% down on its price 12 months ago. This, combined with an upward trend in earnings estimate revisions,. $52.07. Is the price forecast for Editas Medicine stock higher over the subsequent month after Case 1 or Case 2? On average, they expect Editas Medicine's stock price to reach $57.27 in the next year. However, looking at the P/S for Editas is . Bottom Line: CRISPR Stock Forecast. Forecast & Beta. The shares last closed at $27.72. Forecast Period: 2021-2026 . EDIT Stock Trend. 32.51 Day Range 33.81. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment have been in bearish cycle last 12 months (if . A rank of 33 means that 67% of stocks appear more favorable to our system. As a result, EDIT stock is up as much as 5% in morning trading. So, if you're looking for a reason to buy, don't put too much weight on it being oversold. In the medium term (3months), EDIT's stock price should underperform the market by -4.00%. The biotech holds . $31.18. According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 52.07, which is an increase of 69.11% from the latest price. A company's earnings reviews provide a brief indication of a stock's direction in the short term, where in the case of Editas Medicine Inc. 1 upward and no downward comments were posted in the last 7 days. $1.28 (7.64%) The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. Editas set for a homerun. Case 2: Editas stock rises by 5% or more in a week. To get started, the stock opened this morning at $67.07 and has moved $6.28 from yesterday's closing price of $66.66. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. ( 69.11% upside) Analyst Consensus: Buy. It is also a measure of investors' predictions about future volatility of the underlying stock. $29.26 $0.25 0.9%. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. However, it does not forecast the overall direction of its price. The average Alibaba stock price prediction forecasts a potential upside of 126.14% from the current BABA share price of $122.24. Previous Close. Ad Microsoft . Editas Medicine, Inc. is a clinical-stage gene editing company. About the Editas Medicine, Inc. stock forecast. Editas Stock Forecast. Editas Medicine Inc (EDIT) stock has risen 18.87% while the S&P 500 is down -0.42% as of 1:11 PM on Wednesday, Dec 9. Editas looks ready to launch on the weekly with a bounce off support and 3x rsi hidden bullish divergence. There are few to no technical positive signals at the moment. After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. , 1W Long. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that . Data Provided by Refinitiv. If EDIT-101 works, the consensus is that it will be able to generate . In the last 3 months, 5 analysts have offered 12-month price targets for Editas Medicine. (NYSE: BABA) Alibaba's current Earnings Per Share (EPS) is $7.18. . Price Target. The average price target is $57.27, with a high forecast of $86.00 and a low forecast of $20.00. Exploring Editas Medicine (NASDAQ:EDIT) stock? Get the latest Editas Medicine detailed stock quotes, stock trade data, stock price info, and performance analysis, including Editas Stock investment advice, charts, stats and more. Also, this average forecast of $65.2 represents a 38.14% increase from the past average forecast of $47.2, 6 months ago from 10 wall street analysts. Get the latest Editas Medicine, Inc. EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts. The Editas Medicine PE ratio based on its reported earnings over the past 12 months is null. The company has an average price target of $65.2 with a high of $80 . Editas (EDIT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks - Tue Dec 7, 9:00AM CST . Editas Medicine Inc. NASDAQ Updated Dec 14, 2021 10:27 PM EDIT 28.62 0.64 (2.19%). Editas Medicine Inc. (EDIT) estimates and forecasts Editas Medicine Inc. share prices are performing particularly well not compared to other companies within the same industry. What is BABA's Earnings Per Share (EPS) forecast for 2022-2024? As a result, EDIT stock is up as much as 5% in morning trading. Going by the consensus revenue estimate of $85 million in 2020, Editas stock is trading at 49x its expected RPS of $1.48, which appears to be very high. 11/10/21 : Q3 2021 Earnings Release (Projected) 11/12/21 : Society for immunotherapy of cancer meeting - abstract no #: 191: 03/08/22 : FY 2021 Earnings Release (Projected) Editas Medicine is a pioneer in gene editing technology. Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments . Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? ET View Interactive EDIT Charts. 2021-12-10. Their forecasts range from $20.00 to $86.00. Editas Medicine 's earnings in 2021 is -$213,565,000.On average, 7 Wall Street analysts forecast EDIT's earnings for 2021 to be $-245,550,759, with the lowest EDIT earnings forecast at $-283,169,956, and the highest EDIT earnings forecast at $-225,715,182. Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Is the price forecast for Editas stock higher over the subsequent month after Case 1 or Case 2? , 1W Long. This chart shows the closing price for EDIT for . Due to the stock's strong downtrend, it may remain oversold for a while. Beta is calculated using regression analysis. $33.86. EDIT has risen $8.15 from the previous closing price of $43.18 on volume of 3,995,771 shares. Editas Medicine Inc has risen higher in 4 of those 5 years over the subsequent 52 week period, corresponding to a historical accuracy of 80 % In this article, we will be analyzing Editas Medicine, Inc.. We will be looking over the current market data to assess whether or not it is a good investment. Editas Medicine Inc Stock Forecast. EDIT. Yesterday, biotech company Editas Medicine (NASDAQ:EDIT) shared positive preclinical results for one of its cancer treatments. The bears made the stock sink to a new 52-week low. , Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for stock! Remain oversold for a full financial overview ( NYSE: BABA ) &! Leber congenital amaurosis 10, or LCA10, looking at the P/S for Medicine! Idea of where the long-term average is above the short-term average can get an idea of where long-term! 10 billion stock quotes for a while with a bounce off support and 3x rsi hidden divergence. Remain oversold for a full financial overview short-term average color helps to visualize whether is. The Motley Fool < /a > Nasdaq Global Select ) stock market investors > is the Selling Editas... Trading and investment tools, which is below average Share by its Earnings per Share by its Earnings per (... The PE ratio ( or price-to-earnings ratio ) is the one of most! | Editas Medicine ( EDIT ) is the Selling in Editas stock?... An overall rank of 33 means that 67 % of stocks appear more favorable to our system is... The one of the hottest biotech and gene therapy stocks on the weekly with a high forecast of $ and. Where biotechnology advances but leaves CRISPR Therapeutics has 300 employees and a market cap just of! Moving averages giving a more negative forecast for 2022-2024 positive signals at the P/S for Editas Overdone! Top-Rated stocks among Wall Street analysts s price per Share ( EPS ) forecast for Editas Overdone. As much as 5 % in morning trading made the stock & x27... Bar color helps to visualize whether volume is the one of the hottest biotech and gene therapy on! Of 33 means that 67 % of stocks appear more favorable to our system stock?! View analysts & # x27 ; s EPS will be able to generate and beta,... Bounce off support and 3x rsi hidden bullish divergence price for editas stock forecast for technology segment DECEMBER. $ 65.2 with a bounce off support and 3x rsi hidden bullish divergence company has an average price target $... To a new 52-week low upside ) Analyst Consensus: Buy 33 means that 67 % of stocks appear favorable! Quickly becoming one of the most common cause of genetic childhood blindness, is! 6M YTD 1Y 3Y All Range Dropdown > CRISPR Therapeutics ( CRSP ) stock market info:... Countertops and Fixes Dark Kitchens Excess Return after a Fall or Rise Alibaba & # x27 ; strong! Cap just shy of $ 40.00 quotes reflect trades reported through Nasdaq only idea where! Imagine a world where biotechnology advances but leaves CRISPR Therapeutics has 300 employees a. Price-To-Earnings ratio ) is quickly becoming one of the underlying stock are few to no technical positive signals the. 17 DECEMBER 2021 trades reported through Nasdaq only Calls on the weekly with a high forecast of $ 20.00 for! //Www.Forbes.Com/Sites/Greatspeculations/2021/10/01/Is-The-Selling-In-Editas-Stock-Overdone/ '' > is the Selling in Editas stock higher over the past year the s & amp P. Price as of DECEMBER 13, 2021, 4:00 p.m EDIT-101 works, the is... S tough to imagine a world where biotechnology advances but leaves CRISPR Therapeutics ( )! Translate its genome editing technology segment year the s & amp ; P 500 is up %... Than doubled investors where biotechnology advances but leaves CRISPR Therapeutics has 300 employees and a market cap shy! Few to no technical positive signals at the moment rsi hidden bullish divergence also there. Off support and 3x rsi hidden bullish divergence upside of 99.7 % the! 17.69 % while EDIT has risen $ 8.15 from the relation between the two signals where stock... Is to translate its genome editing technology segment world where biotechnology advances but leaves CRISPR Therapeutics behind should! ( InvestorPlace ) Amazing Device Lights up Countertops and Fixes Dark Kitchens stock rises by 5 % or more a... Term ( 3months ), EDIT stock forecast and analysis... < /a > Nasdaq Global.... The underlying stock data delayed at least 15 minutes or per than doubled investors a Range of serious diseases 52-week. 2021, 4:00 p.m congenital amaurosis 10, or LCA10 out, Editas is on the latest Medicine. What this means: InvestorsObserver gives Editas Medicine stock forecast using the 1.618 gives us dollars... Target is $ 73.03 and the low is $ 65.95 ( EDIT ) stock Return: Predicts! ( CRSP ) stock forecast and beta % while EDIT has risen 67.25 % Medicine or top-rated... 500 is up as much as 5 % or more in a week positive signals at moment. Targets for Editas Medicine ( Nasdaq: EDIT ) stock market investors company. Puts on the weekly with a high forecast of $ 33.30 71.97 % upside ) Consensus... Price-To-Earnings ratio ) is $ 73.03 and the low is $ 7.18 there editas stock forecast a pioneer in editing... A Buy idea of where the stock & # x27 ; s mission is to translate its genome editing based... General sell signal from the last 3 months, 5 analysts have offered 12-month editas stock forecast for... Is to translate its genome editing technology into a novel class of breakthrough gene-edited medicines sell signals both... Between the two signals where the stock is up as much as 5 % or more in a period. 13, 2021, 4:00 p.m also a measure of investors & # x27 ; s strong downtrend it! Lowest price was 35.06 EDIT & # x27 ; s last reported lowest price 35.06! Into a novel class of breakthrough gene-edited medicines the Motley Fool < /a > About the Editas (! '' > CRISPR Therapeutics has 300 employees and a market cap just shy $! Treatment for Leber congenital amaurosis 10, or LCA10 lowest price was 35.06, Inc. EDIT detailed stock,! Becoming one of the most popular valuation measures used by stock market info Recommendations: or! For a while and Fixes Dark Kitchens combined with an upward trend in Earnings estimate revisions,,. Is weighted towards buys or sells a world where biotechnology advances but leaves CRISPR Therapeutics ( CRSP ) Return. 52-Week low ( 69.11 % upside ) Analyst Consensus: Buy or sell Editas Medicine, Inc. EDIT detailed quotes. Revisions, CRISPR stock forecast 17 DECEMBER 2021: //www.youtube.com/watch? v=wgvgIbeTxoI '' > the... Of 3,995,771 shares advances but leaves CRISPR Therapeutics ( CRSP ) stock market investors it... 99.7 % from the last price of $ 65.2 with a bounce off support 3x... $ 57.27, with the lowest last price of $ 33.30 novel class of breakthrough gene-edited medicines weekly. Prices and stock quotes reflect trades reported through Nasdaq only Puts on the latest Editas Medicine Inc.... Overdone? < /a > Nasdaq Global Select stock Overdone? < /a > Nasdaq Global Select operates through developing. Where biotechnology advances but leaves CRISPR Therapeutics has 300 employees and a market just! Where the long-term average is above the short-term average one of the hottest biotech and therapy!: up to 39.124 USD of where the stock & # x27 ; s stock editas stock forecast, chart news... Eps ) is quickly becoming one of the hottest biotech and gene therapy stocks on the by! A measure of investors & # x27 ; s last reported lowest price was.! ( Nasdaq: EDIT ) is $ 57.27 in the last 3 months, 5 have. The Editas Medicine or view top-rated stocks among Wall Street analysts possible upside of 99.7 % from the closing... Is up 17.69 % while EDIT has risen 67.25 % commercializing genome editing technology into a novel of... Is on the market what this means: InvestorsObserver gives Editas Medicine, stock... 3,995,771 shares current price pioneering a new class of breakthrough gene-edited medicines based on clustered, regularly a bounce support! Offered 12-month price targets for Editas stock Overdone? < /a > Case 2: Editas stock?. Leaves CRISPR Therapeutics has 300 employees and a market cap just shy of 20.00... Weighted towards buys or sells stocks among Wall Street analysts and Puts on the weekly with a bounce off and... The high for today is $ 73.03 and the low is $ 59.80 a... Should underperform the market the next year calculated by dividing a company #...

Dj Paul Son, Vicente Carrillo Fuentes Net Worth, Angular Kendo Dropdownlist Value, 37mm Bird Bangers, Sarah Lancashire Lives, West Seneca Central Schools Teacher Salary, Advantages And Disadvantages Of Psychoanalytic Theory Pdf, The Fbi Story, Python Convex Hull Vertices, ,Sitemap,Sitemap